Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with HIV had fewer cirrhosis-related complications but greater healthcare utilization.
Timely testing and treatment could improve outcomes for young people who inject drugs.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
With no approved treatments, management of NAFLD and NASH relies on lifestyle changes.
Barriers still stand in the way of making treatment available to all who need it.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
The early cancer is detected, the easier it is to treat.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
Alcoholism-related liver disease was a growing problem even before COVID-19, but the pandemic has dramatically added to the toll.
Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.
A study comparing matched groups of people with and without HIV found that smoking was a powerful cancer risk factor, especially for women.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
New report highlights cancer’s toll on racial and ethnic minorities and other underserved populations.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.